Inflammation and treatment tolerance in Non Hodgkin Lymphoma

Not Applicable

• Conditions: non hodgkin lymphoma; Cancer - Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma

• Registration Number: ACTRN12610000748011
• Lead Sponsor: Australasian Leukaemia and Lymphoma Group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-09-08
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

high grade NHL, participation in either NHL7 or NHL11 Australasian leukaemia and Lymphoma Group trial

Exclusion Criteria

nil

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To evaluate the associations of the neutrophil to lymphocyte ratio (NLR) and the presence of B symptoms at baseline with the incidence and grades of haematological and non-haematological toxicity after chemotherapy[Originally collected at baseline and after chemotherapy, data analysed at the conclusion of this data mining study];To evaluate the associations of the NLR and presence of B symptoms at baseline with the requirement for dose reduction and delay in chemotherapy[Originally collected at baseline and after chemotherapy, data analysed at the conclusion of this data mining study];To evaluate the associations of the NLR and presence of B symptoms at baseline with the requirement and duration of hospitalization for treatment-related toxicities.[Originally collected at baseline and after chemotherapy, data analysed at the conclusion of this data mining study]

Secondary Outcome Measures

Name	Time	Method
To evaluate the associations of the presence of NLR and B symptoms at baseline with response rates, progression free and overall survival[Originally collected at baseline and at trial closure, data analysed at the conclusion of this data mining study];To correlate the baseline neutrophil to lymphocyte ratio (NLR) with other baseline prognostic factors in NHL including B symptoms, International Prognostic Index, disease stage, beta 2 microglobulin and others.[Originally collected at baseline, data analysed at the conclusion of this data mining study];To correlate plasma levels of inflammatory proteins with B symptoms, NLR and other prognostic markers.[Originally collected at baseline, data analysed at the conclusion of this data mining study]